Sunshine Biopharma Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2017. The financial statements are unaudited and consolidated. Unless otherwise noted, amounts are in U.S. dollars.
Business context
The company is developing Adva-27a, a proprietary anticancer drug, and preparing to commercialize licensed generic pharmaceuticals in Canada. It had not generated revenue since inception. The generic products require Canadian regulatory approvals and an appropriate licensed facility; Adva-27a remains in preclinical development.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 or comparison |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expenses | $108,990 | $69,682 |
| Operating loss | $108,990 | $69,682 |
| Interest expense | $9,144 | $6,954 |
| Loss on debt conversion | $76,929 | $253,658 |
| Net loss | $195,702 | $305,294 |
| Comprehensive loss | $194,193 | $315,285 |
| Net cash used in operating activities | $108,037 | $81,598 |
| Cash at period end | $17,143 | $123,337 at March 31, 2016 |
- G&A increased by $39,308, primarily because executive compensation rose by approximately $43,000; accounting and consulting costs also increased, while legal costs declined.
- The net loss narrowed year over year, mainly because the debt-conversion loss was lower. The 2016 period also included $25,000 of litigation settlement proceeds, not received in 2017.
- Operating cash use increased year over year. Financing provided $66,218 in Q1 2017, compared with $164,128 in Q1 2016; investing cash flow was zero in both periods. The company reported a $41,819 decrease in cash before a $1,509 foreign-currency translation adjustment.
- At March 31, total assets were $23,409, current liabilities and total liabilities were $284,452, and shareholders’ deficit was $261,043. Current assets were $17,989, implying a current ratio of approximately 0.06. Revenue-based margins are not meaningful because revenue was zero.
- Current notes payable were $71,439 and related-party notes payable were $183,889. All reported liabilities were current. The company’s common shares outstanding rose from 769.4 million at December 31, 2016 to 817.9 million at March 31, 2017; 204.9 million shares were reserved for note conversion.
- Basic loss per share was reported as $0.00 for both periods, reflecting rounding in the filing; weighted-average common shares were 805.6 million in 2017 versus 215.6 million in 2016.
Material changes, outlook and risks
- Funding and going concern: Management states that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. It requires additional financing and estimates approximately $6 million to fully implement its plans—$1 million for generics and $5 million for drug development—but had no committed financing agreement at the filing date. Additional financing could dilute shareholders or carry restrictive terms or high interest costs.
- Generic-drug plans: The company had licensing agreements for anastrozole, letrozole, bicalutamide and finasteride, but was still seeking product Drug Identification Numbers and a Drug Establishment License. It could not estimate approval timing. Anastrozole sales, if any, would be subject to a 5% royalty on net sales for three years from first sale.
- Adva-27a development: The next planned steps are GMP manufacturing, IND-enabling studies, regulatory filing and Phase I trials. The company said funding constraints had delayed clinical development and anticipated trials in mid-2018, subject to financing. The proposed timeline and any compassionate-use access are uncertain and depend on funding, trial results and regulatory decisions.
- Manufacturing dispute: Lonza reportedly required $687,818 before further work under the manufacturing agreement. The parties had not resolved the disagreement over addressing low yield from a pilot manufacturing run. The filing identifies this matter as a legal proceeding but provides no clear quantified estimate of any potential liability.
- Debt and dilution: Convertible notes carried below-market conversion discounts, including 35% and 39% discounts in disclosed terms. Two related-party notes were renewed to June 30, 2017; one was secured by all company assets and provided for a higher default interest rate and daily penalty. Conversion and future share reservations could materially dilute existing holders.
- Subsequent events: In April, the company disclosed a C$100,000 convertible note, a sale of 34 million shares for approximately $63,912, issuance of 6.7 million shares for laboratory equipment valued at $22,000, and a $65,000 convertible note with 100 million shares reserved for issuance.
- Reporting controls: Management concluded disclosure controls were not effective as of March 31, 2017, citing staffing and expertise gaps, period-end reporting and accounting-policy deficiencies, and weaknesses in transaction review, revenue recognition, inventory controls and accrual accounting. The board said it was reviewing remediation measures.
Important facts for investors to verify
- Available cash, near-term payment obligations and the status, terms and timing of additional financing.
- Progress and costs for the generic-drug approvals, facility licensing and any initial commercial sales.
- Resolution and potential financial consequences of the Lonza manufacturing dispute.
- Adva-27a manufacturing, IND-enabling and clinical milestones, including whether the stated trial timetable remains achievable.
- Potential dilution from convertible notes and reserved shares. The filing’s Note 4 reports 42,528,125 shares issued on debt conversion, while other sections report 42,428,125; this discrepancy should be reconciled.
- Remediation of the disclosed ineffective controls and the accuracy of financial reporting, including the filing’s debt and share-issuance details.